Inclusion Criteria:

          1. Age 1-80 years of age. The pediatric cohort is defined as age younger than 18 years.

          2. Patients with active (blood or bone marrow blasts >5%) relapsed or refractory CD33+
             acute myeloid leukemia (AML) de novo, or secondary. a. Relapsed AML is defined as
             patients that had a first complete remission (CR) before developing recurrent disease.
             b. Refractory AML defined as patients that have not achieved a CR after 2 cycles of
             induction chemotherapy.

          3. Patients must have bone marrow and peripheral blood studies available for confirmation
             of diagnosis of AML; CD33 positivity must be confirmed by either flow cytometry or
             immunohistochemistry; cytogenetics, flow cytometry, and molecular studies (such as
             FMS-like tyrosine kinase-3 [Flt-3] status) will be obtained as per standard practice.

          4. ECOG performance status score </= 2.

          5. Pretreatment calculated or measured creatinine clearance (absolute value) of >= 60
             mL/minute.

          6. Serum bilirubin =< 3.0 mg/dL.

          7. Alanine aminotransferase (ALT) and aspartate aminotransferase (AST) =< 5 times the
             institutional upper limits of normal.

          8. Ejection fraction measured by echocardiogram (ECHO) or multi gated acquisition scan
             (MUGA) >50%.

          9. Subject does not require supplemental oxygen or mechanical ventilation, and oxygen
             saturation by pulse oximetry is 94% or higher on room air.

         10. Negative serum pregnancy test.

         11. Women of child-bearing potential and men must agree to use adequate contraception
             (hormonal or barrier method of birth control or abstinence) prior to study entry and
             for six months following duration of study participation; should a woman become
             pregnant or suspect that she is pregnant while participating on the trial, she should
             inform her treating physician immediately.

         12. Patients who have undergone allo-SCT are eligible if they are at least 3 months post
             SCT, have relapsed AML, are not on treatment or prophylaxis for GVHD, and have no
             active GVHD.

         13. All patients or legally responsible parent or guardian must have the ability to
             understand and willingness to sign a written informed consent

        Exclusion Criteria:

          1. Diagnosis of acute promyelocytic leukemia (APL M3): t(15;17)(q22;q12); (promyelocytic
             leukemia [PML]/retinoic acid receptor [RAR] alpha [a]) and variants excluded.

          2. Patients with extramedullary disease as their sole site of relapsed AML.

          3. Acceptable allogeneic stem cell donor with imminent plans to proceed with allo-SCT.

          4. Known central nervous system (CNS) leukemic involvement that is refractory to
             intrathecal chemotherapy and/or cranio-spinal radiation; patients with a history of
             CNS disease that have been effectively treated to complete remission (< 5 white blood
             cell [WBC]/mm^3 and no blasts in cerebrospinal fluid [CSF]) will be eligible.

          5. Ongoing or active or uncontrolled infection, symptomatic congestive heart failure,
             unstable angina pectoris, cardiac arrhythmia, poorly controlled pulmonary disease or
             psychiatric illness/social situations that would limit compliance with study
             requirements.

          6. Human immunodeficiency virus (HIV) seropositivity, or active hepatitis B or C
             infection based on testing performed within 4 weeks of enrollment.

          7. Currently enrolled in another investigational therapy protocol for AML.

          8. Participants with presence of other active malignancy within 2 years of study entry;
             participants with history of prior malignancy treated with curative intent and
             achieved CR within 2 years are eligible.

          9. Pregnant and lactating women are excluded from this study

         10. Failure of research participant or legally responsible parent or guardian to
             understand the basic elements of the protocol and/or the risks/benefits of
             participating in this phase I study.

         11. History of allergic reactions attributed to compounds of similar chemical or
             biological composition to cetuximab (anti-EGFR).

         12. History of allergic reactions to products containing mouse and bovine protein
             antibodies.

         13. Receiving corticosteroids at >20 mg (age >17) or >0.5mg/kg (age <18) daily prednisone
             dose or equivalent.

         14. Active autoimmune disease requiring systemic immunosuppressive therapy.

         15. Patient, who in the opinion of the investigator, may not be able to comply with the
             safety monitoring requirements of the study.